Three postulates to help identify the cause of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 24, Issue 4, 2011, Pages 657-668

  De La Torre, Jack C ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; amyloid ; cell cycle; cholinergic; Cochrane Central Register of Controlled Trials; inflammation; oxidative stress; postulates; randomized controlled trials; tau; vascular hypothesis

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CELL CYCLE; CHOLINERGIC ACTIVITY; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EVIDENCE BASED PRACTICE; HUMAN; HYPOTHESIS; IMMUNIZATION; INFLAMMATION; META ANALYSIS; META ANALYSIS (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PERFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR BIOLOGY; AGING; AMYLOID PLAQUE; ANIMAL; METABOLISM; PHYSIOLOGY; PSYCHOLOGY;

AGING; ALZHEIMER DISEASE; ANIMALS; HUMANS; OXIDATIVE STRESS; PLAQUE, AMYLOID;

EID: 79959277057     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-101884     Document Type: Article

References (109)

1. Murad MH,Montori VM (2010) Evidence-based medicine: application in Alzheimers disease research. J Alzheimers Dis 20, 935-942.
2. Moher D, Hopewell S, Schulz KF,Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340, c869.
3. Thacker SB (1988) Meta-analysis. A quantitative approach to research integration. JAMA 259, 1685-1689. (Pubitemid 18072195)
4. Greenland S (1994) Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol 140, 290-296.
5. Berlin JA (1995) Invited commentary: benefits of heterogeneity in meta-analysis of data from epidemiologic studies. Am J Epidemiol 142, 383-387.
6. de la Torre JC (2010) Postulates to help validate a causal relationship to Alzheimers disease. Frontiers Neurosci 4, 1-3.
7. Hardy JA, HigginsGA(1992) Alzheimers disease: the amyloid cascade hypothesis. Science 256, 184-185.
8. Selkoe DJ (2001) Alzheimers disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 3, 75-80.
9. Hardy J (1992) An anatomical cascade hypothesis for Alzheimers disease. Trends Neurosci 15, 200-201.
10. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539. (Pubitemid 34288854)
11. Rogers J, Morrison JH (1985) Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimers disease. J Neurosci 5, 2801-2808. (Pubitemid 16232369)
12. Bouras, C, Kovari E, Herrmann FR, Rivara CB, Bailey TL, von Gunten A, Hof PR, Giannakopoulos P (2006) Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J Neuropathol Exp Neurol 65, 235-244.
13. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42, 631-639.
14. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M,Wolfson L (1988) Clinicopathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimers disease. Neurology 38, 1682-1687. (Pubitemid 18265029)
15. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimers disease. Ann Neurol 45, 358-368. (Pubitemid 29120041)
16. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol Apr 58, 376-388. (Pubitemid 29187900)
17. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, K̈ovari E, Perl DP, Morrison JH, Gold G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimers disease. Neurology 60, 1495-1500. (Pubitemid 36559525)
18. Rodrigue KM,Kennedy KM, Park DC (2009) Beta-amyloid deposition and the aging brain. Neuropsychol Rev 19, 436-450.
19. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study 2001. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357, 169-175.
20. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, OKeefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
21. Holmes C, Boche, D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll, JA (2008) Long-term effects of Abeta42 immunisation in Alzheimers disease: follow-up of a randomised, placebo controlled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)
22. Aisen PS (2009) Alzheimers disease therapeutic research: the path forward. Alzheimers Res Ther, 1, 2.
23. Currais A, Hortobágyi T, Soriano S. (2009) The neuronal cell cycle as a mechanism of pathogenesis in Alzheimers disease. Aging (Albany NY). 28, 363-371.
24. Angelo M, Plattner F, Giese KP (2006) Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory. J Neurochem 99, 353-370. (Pubitemid 44477194)
25. Herrup K, Busser JC (1995) The induction of multiple cell cycle events precedes target-related neuronal death. Development 121, 2385-2395.
26. Heintz N (1993) Cell death and the cell cycle: a relationship between transformation and neurodegeneration? Trends Biochem Sci 18, 157-159. (Pubitemid 23142567)
27. Neve RL, McPhie DL (2006) The cell cycle as a therapeutic target for Alzheimers disease. Pharmacol Ther 111, 99-113. (Pubitemid 43786202)
28. Vincent I, Rosado M, Davies P (1996). Mitotic mechanisms in Alzheimers disease? J Cell Biol 132, 413-425.
29. Arendt T, Rodel L, Gartner U, HolzerM(1996). Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimers disease. NeuroReport 7, 3047-3049. (Pubitemid 26426387)
30. Vincent I, Zheng JH, DicksonDW, KressY, Davies P (1998) Mitotic phosphoepitopes precede paired helical filaments in Alzheimers disease. Neurobiol Aging 19, 287-296. (Pubitemid 28470596)
31. Yang Y. Mufson EJ, Herrup K (2003). Neuronal cell death is preceded by cell cycle events at all stages of Alzheimers disease. J Neurosci 23, 2557-2563. (Pubitemid 36418589)
32. Feldberg W (1945) Synthesis of acetylcholine by tissue of the central nervous system. J Physiol 103, 367-402.
33. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34, 247-265. (Pubitemid 8188071)
34. Davies AP, Moloney AJF (1976) Selective loss of cholinergic neurons in Alzheimers disease. Lancet ii, 1403.
35. Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459-496.
36. Whitehouse P, Price DL, Stribble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimers disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237.
37. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, BennettDA, Cochran EJ,Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51, 145-155. (Pubitemid 34111436)
38. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148, 379-397. (Pubitemid 351665469)
39. Raschetti R, Albanese E, Vanacore N, Maggini M (2007) Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 4, e338.
40. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimers disease: systematic review of randomised clinical trials. BMJ 331, 321-327.
41. WeeYongV(2010) Inflammation in neurological disorders: a help or a hindrance? Neuroscientist 16, 408-420.
42. Akiyama H (1994) Inflammatory response in Alzheimers disease. Tohoku J Exp Med 174, 295-303.
43. McGeer PL, McGeer EG, Yasojima K (2000) Alzheimer disease and neuroinflammation. J Neural Transm Suppl 59, 53-57. (Pubitemid 30479406)
44. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
45. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM,Cooper NR, Eikelenboom P, Emmerling M, FiebichBL (2000) Inflammation and Alzheimers disease. Neurobiol. Aging 21, 383-421.
46. Galimberti D, Fenoglio C, Scarpini E (2008) Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci 1, 30-41.
47. Graves AB, White E, Koepsell, TD, Reifler BV, van Belle G, Larson EB, Raskind M (1990) A case-control study of Alzheimers disease. Ann Neurol 28, 766-774.
48. Breitner JC, Haneuse SJ, Walker R, Dublin S, Crane PK, Gray SL, Larson EB (2009) Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899-1905.
49. Jenkinson ML, Bliss MR, Brain AT, Scott DL (1989) Rheumatoid arthritis and senile dementia of the Alzheimers type. Br J Rheumatol 28, 86-88.
50. Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM (1992) A case-control study of Alzheimers disease in China. Neurology 42, 1481-1488.
51. Szekely CA, Zandi PP (2010) Non-steroidal antiinflammatory drugs and Alzheimers disease: the epidemiological evidence. CNS Neurol Disord Drug Targets 9, 132-139.
52. ADAPT Research Group (2007) Naproxen and celecoxib do not preventADin early results from a randomized controlled trial. Neurology 68, 1800-1808.
53. Harman D, Eddy DE, Noffsinger J (1976) Free radical theory of aging: Inhibition of amyloidosis in mice by antioxidants; possible mechanisms. J Am Geriatr Soc 24, 203-210.
54. Guglielmotto M, Tamagno E, Danni O (2009) Oxidative stress and hypoxia contribute to Alzheimers disease pathogenesis: two sides of the same coin. ScientificWorldJournal 9, 781-791.
55. de la Torre JC (2008) Pathophysiology of neuronal energy crisis in Alzheimers disease. Neurodegener Dis, 5, 126-132. (Pubitemid 351347829)
56. Hamel E, Nicolakakis N, Aboulkassim T, Ongali B, Tong XK(2008) Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimers disease. Exp Physiol 93, 116-120. (Pubitemid 350293970)
57. Kong Q, Lin CL (2010) Oxidative damage to RNA: mechanisms, consequences, and diseases. Cell Mol Life Sci 67, 1817-1829.
58. Smith MA, Harris PL, Sayre LM, Perry G (1997) Iron accumulation in Alzheimer disease is a source of redoxgenerated free radicals. Proc Natl Acad Sci U S A 94, 9866-9868. (Pubitemid 27408156)
59. Duracková Z (2010) Some current insights into oxidative stress. Physiol Res 59, 459-469.
60. Cherubini A, Ruggiero C, Polidori MC, Mecccci P: (2005) Potential markers of oxidative stress in stroke. Free Radic Biol Med 39, 841-852.
61. Ballinger SW (2005) Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med 38, 1278-1295. (Pubitemid 40602831)
62. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K (2008) Antioxidants in central nervous system diseases: preclinical promise and translational challenges. J Alzheimers Dis 15, 473-493.
63. ButterfieldDA, SultanaR(2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimers disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 12, 61-72. (Pubitemid 47396301)
64. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA(2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurology 60, 759-767. (Pubitemid 32678256)
65. Smith MA, Sayre LM, Vitek MP, Monnier VM, Perry G. (1995) Early AGEing and Alzheimers. Nature 374, 316.
66. Smith MA et al. (2000) Oxidative stress in Alzheimers disease. Biochim Biophys Acta 1502, 139-144.
67. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW Jr, Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A, Perry G (2010) Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 19, 363-372.
68. Praticò D (2008) Oxidative stress hypothesis in Alzheimers disease: a reappraisal. Trends Pharmacol Sci 29, 609-615.
69. Caviston JP, Holzbaur EL (2006) Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol 16, 530-537. (Pubitemid 44444994)
70. Perlson E, Maday S, Fu MM, Moughamian AJ, Holzbaur EL (2010) Retrograde axonal transport: pathways to cell death? Trends Neurosci, 33, 335-344.
71. Trojanowski JQ, Lee VM (1995) Phosphorylation of paired helical filament tau in Alzheimers disease neurofibrillary lesions: focusing on phosphatases. FASEB J 9, 1570-1576. (Pubitemid 26012845)
72. Alonso AD, Zaidi T, Grundke-Iqbal I, (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A 91, 5562-5566. (Pubitemid 24174368)
73. Iqbal K, Grundke-Iqbal I, Zaidi T (1986) Defective brain microtubule assembly in Alzheimers disease. Lancet, 2, 421-426. (Pubitemid 16047953)
74. G̈otz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276, 529-534. (Pubitemid 32050347)
75. Grundke-Iqbal I, Iqbal K, Quinlan M (1986) Microtubuleassociated protein tau: a component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089. (Pubitemid 17207447)
76. Muresan V, Muresan, Z (2009) Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimers disease? Future Neurol 4, 761-773.
77. Gong CX, Grundke-Iqbal I, Iqbal K (2010) Targeting tau protein in Alzheimers disease. Drugs Aging 27, 351-365.
78. Leenders KL, Perani D, Lammertsma AA, Heather JD, Buckingham P, Healy MJ, Gibbs JM, Wise RJ, Hatazawa J, Herold S (1990) Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain, 113 (Pt 1), 27-47. (Pubitemid 20047108)
79. Paulson OB, Hasselbalch SG, Rostrup E, Knudsen GM, Pelligrino D (2010) Cerebral blood flow response to functional activation. J Cereb Blood Flow Metab, 30, 2-14.
80. de la Torre JC (2000) Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimers pathogenesis. Neurobiol Aging 21, 331-342. (Pubitemid 30387092)
81. Soane L, Kahraman S, Kristian T, Fiskum G, Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J Neurosci Res 85, 3407-3415.
82. Hoyer S (1993) Abnormalities in brain glucose utilization and its impact on cellular and molecular mechanisms in sporadic dementia of Alzheimer type. Ann N Y Acad Sci 695, 77-80. (Pubitemid 23348241)
83. de la Torre JC, Mussivand T (1993) Can disturbed brain microcirculation cause Alzheimers disease? Neurol Res 15, 146-153. (Pubitemid 23166998)
84. Kramer, JH, Reed, BR, Mungas, D, Weiner, MW (2002) Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry 72, 217-220.
85. Dede DS, Yavuz B, Yavuz BB, Cankurtaran M, Halil M, Ulger Z, Cankurtaran ES, Aytemir K, Kabakci G, Ariogul S (2007) Assessment of endothelial function in Alzheimers disease: is Alzheimers disease a vascular disease? J Am Geriatr Soc 55, 1613-1617. (Pubitemid 47508508)
86. de la Torre JC (2010) The vascular hypothesis of Alzheimers disease: bench to bedside and beyond. Neurodeg Dis 7, 116-121.
87. de la Torre JC (2008) Pathophysiology of neuronal energy crisis in Alzheimers disease. Neurodegener Dis 5,126-132. (Pubitemid 351347829)
88. Efimova IY, Efimova NY, Triss SV, Lishmanov YB (2008) Brain perfusion and cognitive function changes in hypertensive patients. Hypertens Res 31, 673-685.
89. Hofman A, Ott A, Breteler MMl (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimers disease in the Rotterdam Study. Lancet 349, 151-154. (Pubitemid 27039193)
90. Lopez OL, Kuller LH, Becker JT, Dulberg C, Sweet RA, Gach HM, Dekosky ST (2007) Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 64, 416-420. (Pubitemid 46425698)
91. Kitagawa K (2010) Cerebral blood flow measurement by PET in hypertensive subjects as a marker of cognitive decline. J Alzheimers Dis 20, 855-859.
92. Komulainen P, Kivipelto M, Lakka, TA, Hassinen M, Helkal, EL, Patja K, Nissinen A, Rauramaa, R. (2007) Carotid intima-media thickness and cognitive function in elderly women: a population-based study. Neuroepidemiology 28, 207-213. (Pubitemid 47573715)
93. Glodzik L, Rusinek H, Brys M, Tsui WH, Switalski R, Mosconi L, Mistur R, Pirraglia E, de Santi S, Li Y, Goldowsky A, de Leon MJ (2010) Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cereb Blood Flow Metab, in press.
94. Novak V, Hajjar I (2010) The relationship between blood pressure and cognitive function. Nat Rev Cardiol 7, 686-698.
95. Reitz C, Tang MX, Manly, J, Mayeux R, Luchsinger JA (2007) Hypertension and the risk of mild cognitive impairment. Arch. Neurol 64, 1734-1740. (Pubitemid 350254935)
96. Encinas M, De Juan, R, Marcos A, Gil P, Barabash A, Fernandez C, De Ugarte C, Cabranes J.A (2003) Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimers disease. Eur J Nucl Med Mol Imaging 30, 1473-1480. (Pubitemid 37356114)
97. Alsop DC, Dai W, Grossman M, Detre JA (2010) Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimers disease. J Alzheimers Dis 20, 871-880.
98. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. Radiology 234, 851-859. (Pubitemid 40250829)
99. Ruitenberg A, den Heiker T, Bakker SL (2005) Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam study. Ann Neurol 57, 789-794. (Pubitemid 40798616)
100. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimers disease. Eur J Nucl Med Mol Imaging, 36, 811-822.
101. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenḧager WH (2002) Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162, 2046-2052. (Pubitemid 35168212)
102. Bosch J,Yusuf S, Pogue J (2002) HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 324, 699-702. (Pubitemid 34259143)
103. Tzourio C, Anderson C, Chapman N (2003) PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163, 1069-1075.
104. Skoog I, Lithell H, Hansson L (2005) SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) Am J Hypertens 18, 1052-1059. (Pubitemid 41139903)
105. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME (2009) Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 7, 250-261.
106. Duron E, HanonO(2010) Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis 20, 903-914
107. Kuhn TS (1996) The Structure of Scientific Revolutions, 3rd Ed., The University of Chicago Press, Chicago, Illinois, p. 15.
108. Hill AB (1965) The environment and disease: association or causation? Proc Royal Soc Med 58, 295-300.
109. Cox DR, Wermuth N (1996) Multivariate Dependencies. Models, Analyses and Interpretation. Chapman and Hall, London.